Hilal Lashuel

2012-2013 Visiting Professor, Standford University. Stanford School of Medicine

2011- Associate Professor of Life Sciences-Brain Mind Institute-EPFL

Dir. Laboratory of Chemical Biology of Neurodegeneration

2005-2011 Assistant Professor of Life Sciences-Brain Mind Institute-EPFL

Dir. Laboratory of Molecular Neurobiology and Neuroproteomics

2005-2008 Director- EPFL Proteomic Core Facility

2002-2004 Instructor of Neurology- Harvard Medical School and Brigham and Women's

Hospital

2001-2002 Sabbatical Fellow- Laboratory for Drug Discovery in Neurodegeneration

Harvard Medical School,

2001-2002 Post-doctoral Fellow- Center for Neurologic Diseases

Harvard Medical School and Brigham and Women's Hospital

Advisor- Prof. Peter T. Lansbury

2000-2001 Research Scientist, The Picower Institute for Medical Research, Great Neck

New York

1994-2000 PhD Student; Texas A&M University and the Scripps Research Institute

Advisor- Prof. Jeffery W. Kelly

1990-1994 B.S. City University of New York, Brooklyn College

Dr. Hilal A. Lashuel received his B.Sc. degree in chemistry from the City University of New York in 1994 and completed his doctoral studies at Texas A&M University and the Scripps Research Institute in 2000. After obtaining his doctoral degree, he became a research fellow at the Picower Institute for Medical Research in Long Island New York. In 2001, he moved to Harvard Medical School and the Brigham and Women's Hospital as a research fellow in the Center for Neurologic Diseases and was later promoted to an instructor in neurology at Harvard Medical School. During his tenure (2001-2004) at Harvard Medical School his work focused on understanding the mechanisms of protein misfolding and fibrillogenesis and the role of these processes in the pathogenesis of Parkinson's and Alzheimer's disease. In 2005 Dr. Lashuel moved Switzerland to join the Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne as a tenure-track assistant professor in neurosciences. Currently, Dr. Lashuel is an associate professor of life sciences and the director of the laboratory of molecular and chemical biology of neurodegeneration. (http://lashuel-lab.epfl.ch/).

Research efforts in the Lashuels laboratory focus on understanding the molecular mechanisms of neurodegeneration and developing novel strategies to diagnose and treat neurodegenerative diseases such as Alzheimers and Parkinsons disease. Research in the Lashuel lab is funded by several international funding agencies and foundations, including the Swiss National Science Foundation, European FP7 program (Marie Curie and ERC grants), Human Science Frontiers, Strauss Foundation, Cure the Huntingtons disease foundation and Michael J Fox foundation and is supported by collaborations with pharmaceutical and biotech companies (http://lashuel-lab.epfl.ch/page-50538-en.html), Nestle, Merck-Serono, AC Immune and Johnson and Johnson.

Dr. Lashuels research has resulted in the characterization of novel quaternary structure intermediates on the amyloid pathway, identification of potential therapeutic targets, and new hypotheses concerning the mechanisms of pathogenesis in Alzheimers disease, Parkinsons disease and related disorders. Dr. Lashuel scientific contribution to this field includes i) more than100 publications in major peer reviewed journals including Nature journals, Cell, PNAS, JBC, J. Neuroscience JACS, and Angewandtie Chemie; ii) three patents on novel strategies for preventing protein aggregation and treating autoimmune and inflammatory diseases; iii) more than 150 invited lectures since 2002 and more than 5500 citations (7800 citation-Google Scholar) since 1996. Dr. Lashuel has received several pre-doctoral and post-doctoral awards and fellowships and was the recipient of two prestigious awards given to young investigators; Human Science Frontiers young investigator research award and the European Research Council (ERC) starting independent researcher grant and the ERC proof of concept award (2013) These awards provide more than $2.5 Million to Dr. Lashuel to translate some of his ideas and projects into novel strategies for diagnosing and treating neurodegenerative diseases such as Alzheimers and Parkinsons disease. Dr. Lashuel has chaired and co-organized several international conferences and serves as an academic editor for PLoS ONE, an associate editor for frontiers of molecular neuroscience, member of the Editorial advisory board of ChemBioChem and ad hoc reviewer for several international scientific journals and funding agencies.

À propos de ce résultat

Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.

Unités associées (2)

Cours enseignés par cette personne (2)

Domaines de recherche associés (157)

Publications associées (221)

Personnes menant des recherches similaires (13)

BIO-480: Neuroscience: from molecular mechanisms to disease

The goal of the course is to guide students through the essential aspects of molecular neuroscience and neurodegenerative diseases. The student will gain the ability to dissect the molecular basis of

BIOENG-430: Selected topics in life sciences

The course presents an overview on how recent advances at the interfaces of biology, biotechnology, engineering, physical sciences, and medicine are 1) shaping the landscape of biomedical research; 2)

Maladie

vignette|320px|The Sick Girl (en français : La Fille malade) de Michael Ancher La maladie est une altération des fonctions ou de la santé d'un organisme vivant. On parle aussi bien de la maladie, se référant à l'ensemble des altérations de santé, que dune maladie, qui désigne alors une entité particulière caractérisée par des causes, des symptômes, une évolution et des possibilités thérapeutiques propres. Un ou une malade est une personne souffrant d'une maladie, qu'elle soit déterminée ou non.

Protéine

redresse=1.36|vignette|Représentation d'une protéine, ici deux sous-unités d'une molécule d'hémoglobine. On observe les représentées en couleur, ainsi que deux des quatre molécules d'hème, qui sont les groupes prosthétiques caractéristiques de cette protéine. redresse=1.36|vignette|Liaison peptidique –CO–NH– au sein d'un polypeptide. Le motif constitue le squelette de la protéine, tandis que les groupes liés aux sont les chaînes latérales des résidus d'acides aminés.

Modification post-traductionnelle

Une modification post-traductionnelle est une modification chimique d'une protéine, réalisée le plus souvent par une enzyme, après sa synthèse ou au cours de sa vie dans la cellule. Généralement cette modification entraîne un changement de la fonction de la protéine considérée, que ce soit au niveau de son action, de sa demi-vie, ou de sa localisation cellulaire.

Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies

Hilal Lashuel

Parkinson's disease (PD), the second most common progressive neurodegenerative disease, develops and progresses for 10-15 years before the clinical diagnostic symptoms of the disease are manifested. F

NATURE PORTFOLIO2022

, , , ,

Background: The development of therapeutics for Parkinson's disease (PD) requires the establishment of biomarker assays to enable stratifying patients, monitoring disease progression, and assessing ta

IOS PRESS2022

Pathological substrate of memory impairment in multiple system atrophy

Hilal Lashuel, Melek Firat Altay

Aims: Synaptic dysfunction in Parkinson's disease is caused by propagation of pathogenic alpha-synuclein between neurons. Previously, in multiple system atrophy (MSA), pathologically characterised by

WILEY2022